Sign In
Buy FDMT
$9.53
+0.260 (+2.80%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
12:00pm, Thursday, 30'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investor
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
12:00pm, Tuesday, 28'th Jan 2025
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ: FDMT). Such investors are adv
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
12:00pm, Sunday, 26'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investor
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
12:00pm, Friday, 24'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investor
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
11:15am, Wednesday, 22'nd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investor
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
06:10pm, Tuesday, 21'st Jan 2025
NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ: FDMT). Such investors are adv
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
12:00pm, Saturday, 18'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investor
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
06:30pm, Thursday, 16'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such inv
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
06:20pm, Wednesday, 13'th Nov 2024
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to loss of $0.24 per share a year ago.
4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones
04:05pm, Wednesday, 13'th Nov 2024
EMERYVILLE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
LOS ANGELES, CA / ACCESSWIRE / November 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular T
LOS ANGELES, CA / ACCESSWIRE / November 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular T
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
11:00am, Saturday, 02'nd Nov 2024
LOS ANGELES, CA / ACCESSWIRE / November 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular T
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular T
4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out
11:00am, Saturday, 26'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of 4D Molecular T
